Literature DB >> 1309720

Identification of a genetic locus essential for capsule sialylation in type III group B streptococci.

M R Wessels1, R F Haft, L M Heggen, C E Rubens.   

Abstract

The type III capsular polysaccharide of group B streptococci (GBS) consists of a linear backbone with short side chains ending in residues of N-acetylneuraminic acid, or sialic acid. The presence of sialic acid on the surface of the organism inhibits activation of the alternative pathway of complement and is thought to be an important element in the virulence function of the capsule. We showed previously that a mutant strain of GBS that expressed a sialic acid-deficient, or asialo, form of the type III polysaccharide was avirulent, supporting a virulence function for capsular sialic acid. We now report the derivation of an asialo capsule mutant from a highly encapsulated wild-type strain of type III GBS, strain COH1, by insertional mutagenesis with transposon Tn916 delta E. In contrast to the wild-type strain, the asialo mutant strain COH1-11 was sensitive to phagocytic killing by human leukocytes in vitro and was relatively avirulent in a neonatal rat model of GBS infection. The asialo mutant accumulated free intracellular sialic acid, suggesting a defect subsequent to sialic acid synthesis in the biosynthetic pathway leading to capsule sialylation. The specific biosynthetic defect in mutant strain COH1-11 was found to be in the activation of free sialic acid to CMP-sialic acid: CMP-sialic acid synthetase activity was present in the wild-type strain COH1 but was not detected in the asialo mutant strain COH1-11. One of the two transposon insertions in the asialo mutant COH1-11 mapped to the same chromosomal location as one of the two Tn916 insertions in the previously reported asialo mutant COH31-21, identifying this site as a genetic locus necessary for expression of CMP-sialic acid synthetase activity. These studies demonstrate that the enzymatic synthesis of CMP-sialic acid by GBS is an essential step in sialylation of the type III capsular polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309720      PMCID: PMC257641          DOI: 10.1128/iai.60.2.392-400.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Diffusion-in-gel methods for immunological analysis.

Authors:  O OUCHTERLONY
Journal:  Prog Allergy       Date:  1958

2.  Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

Authors:  M S Edwards; D L Kasper; H J Jennings; C J Baker; A Nicholson-Weller
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

3.  ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes.

Authors:  B M Gray
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

4.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

Authors:  M E Klegerman; K M Boyer; C K Papierniak; L Levine; S P Gotoff
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

5.  Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus.

Authors:  A O Shigeoka; S H Pincus; N S Rote; H R Hill
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  Structure and biosynthesis of surface polymers containing polysialic acid in Escherichia coli.

Authors:  T E Rohr; F A Troy
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

7.  Molecular cloning of the K1 capsular polysaccharide genes of E. coli.

Authors:  R P Silver; C W Finn; W F Vann; W Aaronson; R Schneerson; P J Kretschmer; C F Garon
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

8.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

9.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Immunodeterminant specificity of human immunity to type III group B streptococcus.

Authors:  D L Kasper; C J Baker; R S Baltimore; J H Crabb; G Schiffman; H J Jennings
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

View more
  29 in total

1.  Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression.

Authors:  D O Chaffin; L M Mentele; C E Rubens
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

2.  Identification of Group B Streptococcus Capsule Type by Use of a Dual Phenotypic/Genotypic Assay.

Authors:  Areej Alhhazmi; Armaan Pandey; Gregory J Tyrrell
Journal:  J Clin Microbiol       Date:  2017-06-14       Impact factor: 5.948

3.  Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation.

Authors:  Ravi Maruvada; Nemani V Prasadarao; C E Rubens
Journal:  FASEB J       Date:  2009-07-16       Impact factor: 5.191

4.  New genetic techniques for group B streptococci: high-efficiency transformation, maintenance of temperature-sensitive pWV01 plasmids, and mutagenesis with Tn917.

Authors:  P E Framson; A Nittayajarn; J Merry; P Youngman; C E Rubens
Journal:  Appl Environ Microbiol       Date:  1997-09       Impact factor: 4.792

5.  Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by group B Streptococcus.

Authors:  G Malin; L C Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

6.  Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci.

Authors:  R F Haft; M R Wessels
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

7.  Group B streptococci (GBS) injure lung endothelium in vitro: GBS invasion and GBS-induced eicosanoid production is greater with microvascular than with pulmonary artery cells.

Authors:  R L Gibson; C Soderland; W R Henderson; E Y Chi; C E Rubens
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  The Streptococcus pyogenes capsule is required for adhesion of bacteria to virus-infected alveolar epithelial cells and lethal bacterial-viral superinfection.

Authors:  Shigefumi Okamoto; Shigetada Kawabata; Yutaka Terao; Hideaki Fujitaka; Yoshinobu Okuno; Shigeyuki Hamada
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Conjugative transfer of the integrative conjugative elements ICESt1 and ICESt3 from Streptococcus thermophilus.

Authors:  Xavier Bellanger; Adam P Roberts; Catherine Morel; Frédéric Choulet; Guillaume Pavlovic; Peter Mullany; Bernard Decaris; Gérard Guédon
Journal:  J Bacteriol       Date:  2009-01-30       Impact factor: 3.490

10.  Genome-Wide Assessment of Streptococcus agalactiae Genes Required for Survival in Human Whole Blood and Plasma.

Authors:  Luchang Zhu; Prasanti Yerramilli; Layne Pruitt; Matthew Ojeda Saavedra; Concepcion C Cantu; Randall J Olsen; Stephen B Beres; Andrew S Waller; James M Musser
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.